Ignite Creation Date:
2024-05-06 @ 6:30 PM
Last Modification Date:
2024-10-26 @ 2:49 PM
Study NCT ID:
NCT05680610
Status:
RECRUITING
Last Update Posted:
2023-01-11
First Post:
2022-12-31
Brief Title:
Follow up of Moderate Aortic Regurge After Mitral Valve Replacement
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Follow up of Moderate Aortic Regurge After Rhumatic Mitral Valve Replacement
Status:
RECRUITING
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Aim of the study is to follow of of moderate aortic regurge after mitral valve replacement to figure out if the aortic regurge has been improved or it is getting worse
Detailed Description:
A considerable proportion of patients who require mitral valve replacement present with a coexisting pathology of the aortic valve AV Rheumatic fever remains the leading cause for combined disease 1 Early series found that one-third of rheumatic hearts exhibited involvement of both mitral and aortic valve The rate increased to 99 when the follow-up period was extended to 20 years The treatment of choice in cases in which one of the valves is moderately affected is questionable Because combined aortic and mitral valve replacement is usually associated with higher risk and poorer long-term survival than replacement of either of the two valves alone 2 In patients with moderate aortic regurgitation who undergo mitral valve surgery according to 2021 ESCEACTS Guidelines the decision to treat the aortic valve is controversial as data show that progression of moderate aortic regurgitation is very slow in patients without aortic dilation 3 in contrast In 2020 AHA guidelines recommended concomitant aortic valve replacement for moderate aortic regurgitation in patients undergoing surgery for ascending aorta coronary artery bypass grafting CABGor mitral valve surgery 4-10 Because of this is a point of conflict we aim in this study to evaluate the saftey to leave moderate aortic regurge without intertvention as regarding operative time postoperative morbidity and mortality and progression of aortic valve regurge
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None